Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Antibody neutralization and escape by HIV-1

An Erratum to this article was published on 08 May 2003

Abstract

Neutralizing antibodies (Nab) are a principal component of an effective human immune response to many pathogens, yet their role in HIV-1 infection is unclear1,2,3,4,5,6. To gain a better understanding of this role, we examined plasma from patients with acute HIV infection. Here we report the detection of autologous Nab as early as 52 days after detection of HIV-specific antibodies. The viral inhibitory activity of Nab resulted in complete replacement of neutralization-sensitive virus by successive populations of resistant virus. Escape virus contained mutations in the env gene that were unexpectedly sparse, did not map generally to known neutralization epitopes, and involved primarily changes in N-linked glycosylation. This pattern of escape, and the exceptional density of HIV-1 envelope glycosylation generally7,8, led us to postulate an evolving ‘glycan shield’ mechanism of neutralization escape whereby selected changes in glycan packing prevent Nab binding but not receptor binding. Direct support for this model was obtained by mutational substitution showing that Nab-selected alterations in glycosylation conferred escape from both autologous antibody and epitope-specific monoclonal antibodies. The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Autologous virus neutralization and escape in subject WEAU.
Figure 2: Envelope sequences of sequential WEAU clones spanning days 15–1,100.
Figure 3: Partial envelope sequences of sequential plasma-derived clones.
Figure 4: Neutralization of virus pseudotyped with naturally occurring or site-directed mutant envelopes.

References

  1. Albert, J. et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107–112 (1990)

    CAS  Article  Google Scholar 

  2. Pilgrim, A. K. et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176, 924–932 (1997)

    CAS  Article  Google Scholar 

  3. Moog, C., Fleury, H. J. A., Pellegrin, I., Kirn, A. & Aubertin, A. M. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71, 3734–3741 (1997)

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Montefiori, D. C., Hill, T. S., Vo, H. T. T., Walker, B. D. & Rosenberg, E. S. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75, 10200–10207 (2001)

    CAS  Article  Google Scholar 

  5. Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 in vivo. Immunity 10, 431–438 (1999)

    CAS  Article  Google Scholar 

  6. Parren, P. W. H. I., Moore, J. P., Burton, D. R. & Sattentau, Q. J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13 (Suppl. A), S137–S162 (1999)

    CAS  PubMed  Google Scholar 

  7. Kuiken, C. L. et al. (eds) Human Retroviruses and AIDS 2000: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences (Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, 2000)

  8. Myers, G. & Lenroot, R. HIV glycosylation: What does it portend? AIDS Res. Hum. Retroviruses 8, 1459–1460 (1992)

    CAS  Article  Google Scholar 

  9. Ramratnam, B. et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354, 1782–1785 (1999)

    CAS  Article  Google Scholar 

  10. Markowitz, M. et al. A novel antiviral intervention results in a more accurate assessment of HIV-1 replication dynamics and T-cell decay in vivo. J. Virol. (in the press)

  11. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117–122 (1995)

    ADS  CAS  Article  Google Scholar 

  12. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205–211 (1997)

    CAS  Article  Google Scholar 

  13. Wei, X. et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896–1905 (2002)

    CAS  Article  Google Scholar 

  14. Kwong, P. D. et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8, 1329–1339 (2000)

    CAS  Article  Google Scholar 

  15. Wyatt, R. et al. The antigenic structure of the human immunodeficiency virus gp120 envelope glycoprotein. Nature 393, 705–711 (1998)

    ADS  CAS  Article  Google Scholar 

  16. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science 280, 1884–1888 (1998)

    ADS  CAS  Article  Google Scholar 

  17. Poignard, P., Saphire, E. O., Parren, P. W. H. I. & Burton, D. R. GP120: Biologic aspects of structural features. Annu. Rev. Immunol. 19, 253–274 (2001)

    CAS  Article  Google Scholar 

  18. Kwong, P. D., Wyatt, R., Sattentau, Q. J., Sodroski, J. & Hendrickson, W. A. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74, 1961–1972 (2000)

    CAS  Article  Google Scholar 

  19. Mizuochi, T. et al. Diversity of oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J. Biol. Chem. 265, 8519–8524 (1990)

    CAS  PubMed  Google Scholar 

  20. Scanlan, C. N. et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α → 2 mannose residues on the outer face of gp120. J. Virol. 76, 7306–7321 (2002)

    CAS  Article  Google Scholar 

  21. Sanders, R. W. et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293–7305 (2002)

    CAS  Article  Google Scholar 

  22. Gorny, M. K. et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76, 9035–9045 (2002)

    CAS  Article  Google Scholar 

  23. Kolchinsky, P., Kiprilov, E. & Sodroski, J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75, 2041–2050 (2001)

    CAS  Article  Google Scholar 

  24. Chackerian, B., Rudensey, L. M. & Overbaugh, J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 71, 7719–7727 (1997)

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Back, N. K. et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199, 431–438 (1994)

    CAS  Article  Google Scholar 

  26. Reitter, J. N., Means, R. E. & Desrosiers, R. C. A role for carbohydrates in immune evasion in AIDS. Nature Med. 4, 679–684 (1998)

    CAS  Article  Google Scholar 

  27. Kwong, P. D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678–682 (2002)

    ADS  CAS  Article  Google Scholar 

  28. Stewart, J. J., Watts, P. & Litwin, S. Profile of a Quasispecies: The Selected Mutational Landscape of HIV and Influenza (Vrije Univ., Amsterdam, 1999)

    Google Scholar 

  29. Nowak, M. A. & May, R. M. Viral Dynamics (Oxford Univ. Press, Oxford, 2000)

    Google Scholar 

  30. Richman, D., Wrin, T., Little, S. & Petropoulos, C. Rapid evolution of the neutralizing antibody response to human immunodeficiency virus type 1 infection. Proc. Natl Acad. Sci. USA (in the press)

Download references

Acknowledgements

We thank S. Zolla-Pazner for HIV-1 V3 specific monoclonal antibodies; D. Burton, B. Korber, J. Mascola, D. Montefiore, J. Moore, L. Shapiro and R. Wyatt for discussions; S. Meleth for assistance with statistical analyses; and W. Abbott for artwork and technical assistance. This work was supported by the Acute Infection Early Disease Research Program of the National Institutes of Allergy and Infectious Diseases, the UAB Center for AIDS Research, the UAB General Clinical Research Center, and the National Institutes of Health. We also thank Bristol-Myers Squibb, GlaxoSmithKline, Agouron and Merck for continuing support of acute HIV-1 infection studies.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to George M. Shaw.

Ethics declarations

Competing interests

The authors declare that they have no competing financial interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wei, X., Decker, J., Wang, S. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312 (2003). https://doi.org/10.1038/nature01470

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature01470

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing